[go: up one dir, main page]

WO2000061638A3 - Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg - Google Patents

Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg Download PDF

Info

Publication number
WO2000061638A3
WO2000061638A3 PCT/US2000/009776 US0009776W WO0061638A3 WO 2000061638 A3 WO2000061638 A3 WO 2000061638A3 US 0009776 W US0009776 W US 0009776W WO 0061638 A3 WO0061638 A3 WO 0061638A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcgn
hcg
nicked
choriocarcinoma
isoforms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/009776
Other languages
English (en)
Other versions
WO2000061638A2 (fr
Inventor
Alexander Krichevsky
Steven Birken
John O'connor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Priority to CA002369923A priority Critical patent/CA2369923A1/fr
Priority to AU42349/00A priority patent/AU4234900A/en
Publication of WO2000061638A2 publication Critical patent/WO2000061638A2/fr
Publication of WO2000061638A3 publication Critical patent/WO2000061638A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La gonadotrophine chorionique humaine (hCG) existe dans le sang et l'urine en tant que variété d'isoformes. L'une d'elles, qui contient des clivages de liaisons peptidiques à l'intérieur de sa sous unité bêta, est désignée hCG coupée (hCGn). Cette isoforme de la hCGn est plus courante dans l'urine des patients présentant certaines malignités et éventuellement dans d'autres maladies de grossesse. L'invention porte sur deux anticorps monoclonaux à une isoforme de la hCGn isolée chez un patient choriocarcinome. Deux analyses immunométriques sur site ont été élaborées à l'aide de ces anticorps, désignés B151 et B152. Le premier présente une bonne spécificité pour hCGn indépendante de la source de la hCGn, forme évacuée par des patients choriocarcinomes, ou la forme de la hCGn provenant de grossesses normales. L'autre anticorps, B152, est exceptionnellement sensible aux fractions glucidiques de hCG choriocarcinome, coupée ou non, étant donné que sa reconnaissance de ligand est fonction des différences glucidiques plutôt que des différences de liaisons peptidiques. Ces deux analyses immunométriques apportent de nouveaux outils de diagnostic fondés sur le mesurage direct de ces isoformes de la hCG.
PCT/US2000/009776 1999-04-12 2000-04-12 Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg Ceased WO2000061638A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002369923A CA2369923A1 (fr) 1999-04-12 2000-04-12 Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg
AU42349/00A AU4234900A (en) 1999-04-12 2000-04-12 Detection of cancer and abnormal pregnancy using monoclonal antibodies specific for hcg isoforms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12884599P 1999-04-12 1999-04-12
US60/128,845 1999-04-12

Publications (2)

Publication Number Publication Date
WO2000061638A2 WO2000061638A2 (fr) 2000-10-19
WO2000061638A3 true WO2000061638A3 (fr) 2001-04-19

Family

ID=22437271

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/009776 Ceased WO2000061638A2 (fr) 1999-04-12 2000-04-12 Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg

Country Status (3)

Country Link
AU (1) AU4234900A (fr)
CA (1) CA2369923A1 (fr)
WO (1) WO2000061638A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003012445A1 (fr) 2001-07-30 2003-02-13 Quest Diagnostics Investments Incorporated Procedes et trousses de detection des ita dans un echantillon biologique
WO2005095458A1 (fr) * 2004-04-02 2005-10-13 The Talwar Research Foundation Anticorps monoclonal chimerique destine a se lier selectivement a hcg avec une haute affinite

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010282A1 (fr) * 1996-09-06 1998-03-12 Yale University Depistage prenatal du syndrome de down a l'aide de gonadotrophine hyperglycosylee
WO1999041584A2 (fr) * 1998-02-03 1999-08-19 The Trustees Of Columbia University In The City Of New York METHODES DE PREVISION DE L'ISSUE D'UNE GROSSESSE CHEZ UN SUJET PAR DOSAGE BIOLOGIQUE DE hCG

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010282A1 (fr) * 1996-09-06 1998-03-12 Yale University Depistage prenatal du syndrome de down a l'aide de gonadotrophine hyperglycosylee
WO1999041584A2 (fr) * 1998-02-03 1999-08-19 The Trustees Of Columbia University In The City Of New York METHODES DE PREVISION DE L'ISSUE D'UNE GROSSESSE CHEZ UN SUJET PAR DOSAGE BIOLOGIQUE DE hCG

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
A. KRICHEVSKY ET AL.: "Development, characterization, and application of monoclonal antibodies to the native and synthetic betaCOOH-terminal portion of human chorionic gonadotropin (hCG) that distinguish between the native and desialylated forms of hCG.", ENDOCRINOLOGY, vol. 134, no. 3, March 1994 (1994-03-01), Philadelphia, PA, USA, pages 1139 - 1145, XP000939398 *
G. KOVALEVSKAYA ET AL.: "Early pregnancy human chorionic gonadotropin (hCG) isoforms measured by an immunometric assay for choriocarcinoma-like hCG.", THE JOURNAL OF ENDOCRINOLOGY, vol. 161, no. 1, April 1999 (1999-04-01), Bristol, GB, pages 99 - 106, XP000939395 *
G. KOVALEVSKAYA ET AL.: "Evaluation of nicked human chorionic gonadotropin content in clinical specimens by a specific immunometric assay.", CLINICAL CHEMISTRY, vol. 45, no. 1, January 1999 (1999-01-01), Washington, DC, USA, pages 68 - 77, XP000946000 *
J. BIDART ET AL.: "Monoclonal antibodies to the free beta-subunit of human chorionic gonadotropin define three distinct antigenic domains and distinguish between intact and nicked molecules.", ENDOCRINOLOGY, vol. 131, no. 4, October 1992 (1992-10-01), Philadelphia, PA, USA, pages 1832 - 1840, XP000939365 *
J. O'CONNOR ET AL.: "Recent advances in the chemistry and immunochemistry of human chorionic gonadotropin: impact on clinical measurement.", ENDOCRINE REVIEWS, vol. 15, no. 5, 1994, Baltimore, MD, USA, pages 650 - 683, XP000939376 *
L. COLE ET AL.: "Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening.", PRENATAL DIAGNOSIS, vol. 18, no. 9, September 1998 (1998-09-01), Chichester, GB, pages 926 - 933, XP000939392 *
P. BERGER ET AL.: "Variants of human chorionic gonadotropin from pregnant women and tumor patients recognized by monoclonal antibodies.", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 77, no. 2, August 1993 (1993-08-01), Philadelphia, PA, USA, pages 347 - 351, XP000939386 *
S. BIRKEN ET AL.: "Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient.", ENDOCRINE, vol. 10, no. 2, April 1999 (1999-04-01), Totowa, NJ, USA, pages 137 - 144, XP000939394 *

Also Published As

Publication number Publication date
AU4234900A (en) 2000-11-14
CA2369923A1 (fr) 2000-10-19
WO2000061638A2 (fr) 2000-10-19

Similar Documents

Publication Publication Date Title
Anthony et al. Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins
Alfthan et al. Elevation of free β subunit of human choriogonadotropin and core β fragment of human choriogonadotropin in the serum and urine of patients with malignant pancreatic and biliary disease
US9541563B2 (en) Methods for predicting pregnancy outcome in a subject by hCG assay
Cole et al. Hyperglycosylated hCG (invasive trophoblast antigen, ITA) a key antigen for early pregnancy detection
AU778130B2 (en) Methods for predicting pregnancy outcome in a subject by hCG assay
Ismail et al. Effect of abnormal sex-chromosome complements on urinary testosterone levels
ES2070488T5 (es) Procedimiento para la diagnosis de enfermedades tumorales.
Birken et al. Analysis of human choriogonadotropin core 2 o-glycan isoforms
AUPO943297A0 (en) Diagnostic test for alzheimer's disease
US20020031781A1 (en) Signal enhancement of bispecific antibody-polymer probe for immunoassay use
Yoo et al. Synchronous elevation of soluble intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) correlates with gastric cancer progression
WO2000061638A3 (fr) Detection de cancer et de grossesse anormale au moyen d'anticorps monoclonaux specifiques pour des isoformes de la hcg
Mardanian et al. Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome
Kovalevskaya et al. Hyperglycosylated HCG expression in pregnancy: cellular origin and clinical applications
FI941284A0 (fi) Menetelmä mahalaukun epiteelivaurion havaitsemiseksi
Corey et al. Characterization of 10 new monoclonal antibodies against prostate‐specific antigen by analysis of affinity, specificity and function in sandwich assays
Kinugasa et al. Combination Assay of Urinary β‐Core Fragment of Human Chorionic Gonadotropin with Serum Tumor Markers in Gynecologic Cancers
Javadpour Biologic tumor markers in management of testicular and bladder cancer
US7198954B1 (en) Methods for predicting pregnancy outcome in a subject by hCG assay
Recklies et al. A radioimmunoassay for total human cathepsin B
Bersinger et al. Pregnancy‐associated plasma protein A (PA‐A) in non‐pregnant subjects
FI100557B (fi) Vapaan trypsinogeeni-2:n määritys
Kulkarni et al. A cross sectional study to compare serum beta 2 microglobulin levels in oral leukoplakia and oral squamous cell carcinoma patients
US5593898A (en) Diagnostic method for the immunological determination of NCAM
CA2328416A1 (fr) Anticorps et leur utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2369923

Country of ref document: CA

Ref country code: CA

Ref document number: 2369923

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP